검색어 : 통합검색[Chase Nicholas]
총 543건 중 543건 출력
, 52/55 페이지
-
511
- EVEREST: Everolimus for renal cancer ensuing surgical therapy-A phase III study (SWOG S0931, NCT01120249).
- Ryan, Christopher W.; Tangen, Catherine; Heath, Elisabeth I.; Stein, Mark N.; Meng, Maxwell; Alva, Ajjai Shivaram; Pal, Sumanta K.; Puzanov, Igor; Clark, Joseph I.; Choueiri, Toni K.; Agarwal, Neeraj; Uzzo, Robert; Haas, Naomi B.; Synold, Timothy W.; Plets, Melissa; Vaishampayan, Ulka N.; Shuch, Brian M.; Vogelzang, Nicholas J.; Thompson, Ian M; Lara, Primo “Lucky” N.; Oregon Health & Science University, Knight Cancer Institute, Portland, OR; ; SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; ; Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI; ; Columbia University Medical Center, New York, NY; ; Department of Urology, University of California San Francisco, San Francisco, CA; ; University of Michigan Rogel Comprehensive Cancer Center, Ann Arbor, MI; ; Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA; ; Roswell Park Comprehensive Cancer Center, Buffalo, NY; ; Loyola University Chicago Medical Center, Maywood, IL; ; Dana-Farber Cancer Institute, Boston, MA; ; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; ; Fox Chase Cancer Center, Temple Health, Philadelphia, PA; ; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; ; City of Hope National Medical Center, Duarte, CA; ; SWOG Stat; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.40, 2022, pp.LBA4500-LBA4500)
-
512
- Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.
- Sweeney, Christopher; Chen, Yu-Hui; Carducci, Michael Anthony; Liu, Glenn; Jarrard, David Frasier; Eisenberger, Mario A.; Wong, Yu-Ning; Hahn, Noah M.; Kohli, Manish; Vogelzang, Nicholas J.; Cooney, Matthew M.; Dreicer, Robert; Picus, Joel; Shevrin, Daniel H.; Hussain, Maha; Garcia, Jorge A.; DiPaola, Robert S.; Dana-Farber Cancer Institute, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Wisconsin Carbone Cancer Center, Madison, WI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Fox Chase Cancer Center, Philadelphia, PA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Division of Oncology, Washington University in St. Louis, St. Louis, MO; NorthShore University HealthSystem, Evanston, IL; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Cleveland Clinic, Cleveland, OH; Rutgers Biomedical and Health Sciences, Ne; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.32, 2014, pp.LBA2-LBA2)
-
513
- Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.
- Tripathi, Abhishek; Chen, Yu-Hui; Jarrard, David Frazier; Hahn, Noah M.; Garcia, Jorge A.; Dreicer, Robert; Liu, Glenn; Hussain, Maha H. A.; Shevrin, Daniel H.; Cooney, Matthew M.; Eisenberger, Mario A.; Kohli, Manish; Plimack, Elizabeth R.; Vogelzang, Nicholas J.; Picus, Joel; Carducci, Michael Anthony; DiPaola, Robert S.; Sweeney, Christopher; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK; ; Dana-Farber Cancer Institute, Boston, MA; ; University of Wisconsin Carbone Cancer Center, Madison, WI; ; Johns Hopkins Greenberg Bladder Center Institute, Johns Hopkins School of Medicine, Baltimore, MD; ; University Hospitals Seidman Cancer Center, Cleveland, OH; ; University of Virginia Cancer Center, Charlottesville, VA; ; University of Wisconsin Carbone Cancer Center, Madison, WI; ; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; ; NorthShore University Health System, Evanston, IL; ; University Hospitals Case Medical Center, Cleveland, OH; ; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; ; Huntsman Cancer Institute, Salt Lake City, UT; ; Fox Chase Cancer Center, Philadelphia, PA; ; Comprehensive Cancer Centers, Las Vegas, NV; ; Washington University School of Medicine, Division of Medical Oncology, St. Louis, MO; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.40, 2022, pp.5081-5081)
-
514
- Early postoperative radiotherapy is associated with improved outcomes over late postoperative radiotherapy in the management of completely resected (R0) Stage IIIA-N2 non-small cell lung cancer
- Wang, Huan-Huan; Deng, Lei; Wen, Qing-Lian; Zhang, Chun-Ze; Zaorsky, Nicholas G.; Zhang, Bai-Lin; Chen, Jie; Zeng, Xian-Liang; Cui, Yao-Li; Shi, Yang-Yang; Hou, Hai-Ling; Wang, Wei; Jiang, Bo; Wang, Jun; Pang, Qing-Song; Zhao, Lu-Jun; Yuan, Zhi-Yong; Wang, Ping; Meng, Mao-Bin; Department of Radiation Oncology and CyberKnife Center, Tianjin's Clinical Research Center for Cancer and Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin 300060, China; Department of Thoracic Cancer, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China School of Medicine, Sichuan University, Chengdu 610041, China; Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou 646000, China; Department of Surgery, Nankai University Tianjin People's Hospital, Tianjin People's Hospital, Tianjin 300121, China; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA; Department of Radiation Oncology and CyberKnife Center, Tianjin's Clinical Research Center for Cancer and Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical R; (Oncotarget, v.8, 2017, pp.62998-63013)
-
515
- Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)
- Agarwal, Neeraj; Tangen, Catherine M.; Hussain, Maha H.A.; Gupta, Shilpa; Plets, Melissa; Lara, Primo N.; Harzstark, Andrea L.; Twardowski, Przemyslaw W.; Paller, Channing J.; Zylla, Dylan; Zibelman, Matthew R.; Levine, Ellis; Roth, Bruce J.; Goldkorn, Amir; Vaena, Daniel A.; Kohli, Manish; Crispino, Tony; Vogelzang, Nicholas J.; Thompson Jr, Ian M.; Quinn, David I.; University of Utah Huntsman Cancer Institute, Salt Lake City, UT; SWOG Statistics and Data Management Center, Seattle, WA; Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; SWOG Statistics and Data Management Center, Seattle, WA; UC Davis Comprehensive Cancer Center, Sacramento, CA; Kaiser Permanente-Oakland, Oakland, CA; John Wayne Cancer Institute, Santa Monica, CA; Johns Hopkins University School of Medicine, Baltimore, MD; Metro Minnesota CCRC/Park Nicollet Clinic, St Louis Park, MN; Fox Chase Cancer Center, Philadelphia, PA; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Washington University School of Medicine, St Louis, MO; USC, Norris Comprehensive Cancer Center, Los Angeles, CA; University of Iowa, Iowa City, IA; University of Utah Huntsman Cancer Institute, Salt Lake City, UT; UsTOO Prostate Cancer Support and Education Las Vegas Chapter, Las Vegas, NV; Comprehe; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.40, 2022, pp.3301-3309)
-
516
- MIFlowCyt: The minimum information about a flow cytometry experiment
- Lee, Jamie A.; Spidlen, Josef; Boyce, Keith; Cai, Jennifer; Crosbie, Nicholas; Dalphin, Mark; Furlong, Jeff; Gasparetto, Maura; Goldberg, Michael; Goralczyk, Elizabeth M.; Hyun, Bill; Jansen, Kirstin; Kollmann, Tobias; Kong, Megan; Leif, Robert; McWeeney, Shannon; Moloshok, Thomas D.; Moore, Wayne; Nolan, Garry; Nolan, John; Nikolich-Zugich, Janko; Parrish, David; Purcell, Barclay; Qian, Yu; Selvaraj, Biruntha; Smith, Clayton; Tchuvatkina, Olga; Wertheimer, Anne; Wilkinson, Peter; Wilson, Christopher; Wood, James; Zigon, Robert; Scheuermann, Richard H.; Brinkman, Ryan R.; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas 75390; Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada V5Z 1L3; Immune Tolerance Network, Pittsburgh, Pennsylvania 15238; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas 75390; Inivai Technologies, Mentone 3194, Victoria, Australia; Amgen Inc., Thousand Oaks, California 91320; Department of Immunology, University of Washington, Seattle, Washington 98195; Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada V5Z 1L3; BD Biosciences, San Jose, California 95131; Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111; Laboratory for Cell Analysis, University of California, San Francisco, California 94143-0808; Department of Immunology, University of Washington, Seattle, Washington 98195; Vaccine Evaluation Center, Child and Family Research Institute, Department of Pediatrics, University of British Co; (Cytometry. the journal of the International Society for Analytical Cytology. Part A, v.a73, 2008, pp.926-930)
-
517
- Lower PSA at 7 months is prognostic for improved overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel (D).
- Harshman, Lauren Christine; Chen, Yu-Hui; Liu, Glenn; Carducci, Michael Anthony; Jarrard, David Frazier; Dreicer, Robert; Hahn, Noah M.; Garcia, Jorge A.; Hussain, Maha; Shevrin, Daniel H.; Eisenberger, Mario A.; Kohli, Manish; Wong, Yu-Ning; Cooney, Matthew M.; Vogelzang, Nicholas J.; Picus, Joel; DiPaola, Robert S.; Sweeney, Christopher; Dana-Farber Cancer Institute, Boston, MA; ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; ; University of Wisconsin Carbone Cancer Center, Madison, WI; ; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; ; University of Wisconsin Hosp and Clinics, Madison, WI; ; University of Virginia, Charlottesville, VA; ; Johns Hopkins University, Baltimore, MD; ; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; ; University of Michigan, Ann Arbor, MI; ; NorthShore University Health System, Evanston, IL; ; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; ; Mayo Clinic, Rochester, MN; ; Fox Chase Cancer Center, Philadelphia, PA; ; University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; ; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; ; Division of Oncology, Washington University in St. Louis, St. Louis, MO; ; University of Kentucky; ; Dana; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.35, 2017, pp.137-137)
-
518
- Multi-center, retrospective study of first-line systemic therapy ± immune checkpoint inhibition for metastatic neuroendocrine carcinoma of the urinary tract.
- Collier, Katharine A.; Simon, Nicholas I.; Taylor, Amy K; Hemenway, Gregory; Rose, Tracy L; Eule, Corbin Jeffrey; Tripathi, Nishita; Rodman, Christopher; Kalluri, Uttam; Farooq, Muhammad Zain; McKay, Rana R.; Jain, Rohit K.; Sonpavde, Guru P.; Sweis, Randy F.; Agarwal, Neeraj; Lam, Elaine T.; Zibelman, Matthew R.; Emamekhoo, Hamid; Apolo, Andrea B.; Mortazavi, Amir; The Ohio State University Comprehensive Cancer Center, Division of Medical Oncology, Columbus, OH; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; Carbone Cancer Center, University of Wisconsin, Madison, WI; Fox Chase Cancer Center, Philadelphia, PA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; University of Colorado Comprehensive Cancer Center, Aurora, CO; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Moores Cancer Center, University of California San Diego, La Jolla, CA; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Bo; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.41, 2023, pp.467-467)
-
519
- Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.
- Sweeney, Christopher; Chen, Yu-Hui; Carducci, Michael Anthony; Liu, Glenn; Jarrard, David Frasier; Eisenberger, Mario A.; Wong, Yu-Ning; Hahn, Noah M.; Kohli, Manish; Vogelzang, Nicholas J.; Cooney, Matthew M.; Dreicer, Robert; Picus, Joel; Shevrin, Daniel H.; Hussain, Maha; Garcia, Jorge A.; DiPaola, Robert S.; Dana-Farber Cancer Institute, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Wisconsin Carbone Cancer Center, Madison, WI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Fox Chase Cancer Center, Philadelphia, PA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Division of Oncology, Washington University in St. Louis, St. Louis, MO; NorthShore University HealthSystem, Evanston, IL; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Cleveland Clinic, Cleveland, OH; Rutgers Biomedical and Health Sciences, Ne; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.32, 2014, pp.LBA2-LBA2)
-
520
- Impact of PSA nadir on long-term survival in metastatic hormone-sensitive prostate cancer: Final 10-year analysis of the ECOG-ACRIN E3805 CHAARTED trial.
- Tripathi, Abhishek; Chen, Yu-Hui; Jarrard, David Frazier; Garcia, Jorge A.; Dreicer, Robert; Liu, Glenn; Hussain, Maha H. A.; Shevrin, Daniel; Cooney, Matthew M.; Eisenberger, Mario A.; Kohli, Manish; Plimack, Elizabeth R.; Vogelzang, Nicholas J.; Picus, Joel; Carducci, Michael A; DiPaola, Robert S.; Sweeney, Christopher; City of Hope Comprehensive Cancer Center, Duarte, CA; Dana-Farber Cancer Institute, Boston, MA; University of Wisconsin-Madison, Madison, WI; Division of Solid Tumor Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; University of Virginia School of Medicine, Charlottesville, VA; University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI; Northwestern University, Feinberg School of Medicine, Chicago, IL; Endeavor Health, Evanston, IL; Tempus AI, Chicago, IL; Johns Hopkins University, Baltimore, MD; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Washington University in St. Louis, St. Louis, MO; Johns Hopkins, Baltimore, MD; University of Kentucky College of Medicine, Lexington, KY; Dana-Fa; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.43, 2025, pp.167-167)
QUICK MENU
